CytomX Therapeutics Price to Book Ratio 2014-2022 | CTMX
Historical price to book ratio values for CytomX Therapeutics (CTMX) over the last 10 years. The current price to book ratio for CytomX Therapeutics as of March 23, 2023 is 4.03.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| CytomX Therapeutics Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2023-03-24 |
1.70 |
|
3.94 |
| 2022-09-30 |
1.45 |
$0.43 |
3.36 |
| 2022-06-30 |
1.83 |
$0.74 |
2.47 |
| 2022-03-31 |
2.67 |
$1.04 |
2.56 |
| 2021-12-31 |
4.33 |
$1.37 |
3.17 |
| 2021-09-30 |
5.09 |
$1.71 |
2.97 |
| 2021-06-30 |
6.33 |
$2.01 |
3.15 |
| 2021-03-31 |
7.73 |
$2.25 |
3.44 |
| 2020-12-31 |
6.55 |
$1.03 |
6.35 |
| 2020-09-30 |
6.65 |
$1.04 |
6.40 |
| 2020-06-30 |
8.33 |
$1.27 |
6.54 |
| 2019-12-31 |
8.31 |
$1.12 |
7.40 |
| 2019-09-30 |
7.38 |
$1.81 |
4.08 |
| 2019-06-30 |
11.22 |
$2.24 |
5.02 |
| 2019-03-31 |
10.75 |
$2.71 |
3.96 |
| 2018-12-31 |
15.10 |
$2.90 |
5.20 |
| 2018-09-30 |
18.50 |
$3.50 |
5.28 |
| 2018-06-30 |
22.86 |
$1.05 |
21.68 |
| 2018-03-31 |
28.45 |
$1.28 |
22.29 |
| 2017-12-31 |
21.11 |
$1.82 |
11.62 |
| 2017-09-30 |
18.17 |
$1.23 |
14.82 |
| 2017-06-30 |
15.50 |
$1.42 |
10.93 |
| 2017-03-31 |
17.27 |
$2.01 |
8.59 |
| 2020-03-31 |
7.67 |
$1.52 |
5.05 |
| 2016-12-31 |
10.99 |
$2.15 |
5.11 |
| 2016-09-30 |
15.68 |
$2.46 |
6.38 |
| 2016-06-30 |
10.22 |
$2.80 |
3.65 |
| 2016-03-31 |
12.90 |
$3.12 |
4.13 |
| 2015-12-31 |
20.87 |
$3.50 |
5.97 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.115B |
$0.070B |
|
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
|
